[Primary diffuse large B-cell lymphoma of the uterine cervix - case report]. / Pierwotny chloniak rozlany z duzych komórek B szyjki macicy - opis przypadku.

We present a case of a 54-year-old woman treated for stage IIAE primary diffuse large B-cell lymphoma (DLBCL) of the uterine cervix. The CHOP chemotherapy regimen was started. After the diagnosis of lymphoma of DLBCL CD20+ type was confirmed, rituximab was added to the therapy. Within systemic therapy, the patient received two cycles of CHOP and six cycles of R-CHOP altogether. After treatment completion, total remission of the lesions was observed on computed tomography. Twenty-four months after therapy completion, the patient is disease-free with no signs of recurrence.

Evaluation of vinorelbine-based chemotherapy as the second or further-line treatment in patients with metastatic breast cancer.

AIM OF THE STUDY: The study examined the response rate, response duration and toxicity of vinorelbine and fluorouracil or vinorelbine alone in pretreated metastatic breast cancer. MATERIAL AND METHODS: Between June 2001 and September 2009, a group of 103 patients with locally advanced or metastatic breast cancer, who had progressed after anthracycline/taxane chemotherapy, was treated with a vinorelbine-based regimen. The treatment consisted of vinorelbine 25 mg/m(2) and 5-fluorouracil (5-FU) 500 mg/m(2) administered intravenously on days 1 and 8 of each cycle (53 patients) or vinorelbine alone at a dose of 30 mg/m(2) on day 1 and 8 of the cycle, every 3 weeks (50 patients). Patients received chemotherapy as a second or further line of therapy. Treatment was continued until disease progression or unacceptable toxicity. The median age of patients treated with vinorelbine with 5FU was 54 years (range 38-76), and 55.5 years (range 38-73) in the group receiving vinorelbine monotherapy. A total of 417 cycles of chemotherapy were administered - 177 cycles of vinorelbine with 5-FU and 137 cycles of vinorelbine monotherapy. Patients were treated for a median of 4 cycles (range: 1 to 11 cycles). The evaluation of treatment effect was possible in 93 patients (10 patients received only one treatment cycle). RESULTS: The overall response rate (ORR) was 17% (7), including 2 (4%) complete responses (CR) and 5 (10.5%) partial responses (PR). Stable disease (SD) was observed in 50% of patients receiving vinorelbine with 5-FU (24 patients). In a group receiving vinorelbine alone the ORR was 20% (9), including 9 PR (20%) and 16 SD (35.5%). The median time to progression (TTP) for the entire group was 18 weeks (95% CI), 22 weeks among patients treated with vinorelbine with 5-FU and 16 weeks for a second group. The most common hematologic adverse events were neutropenia (20% of cycles) and thrombocytopenia (4%), with grade 3/4 incidence of 8% and 1.5% [according to National Cancer Institute Common Toxicity Criteria (NCI CTC)]. Nausea and vomiting were the most frequent non-hematologic forms of toxicity, occurring in 13% of cycles. The doses of cytotoxics were reduced in 26 (25%) cases. There were no treatment-related deaths. CONCLUSIONS: Vinorelbine alone or in combination with 5-FU is an effective and safe treatment for pretreated advanced/ metastatic breast cancer patients. The combination of vinorelbine with 5-FU appears to be a more efficacious regimen than vinorelbine alone.

[Chemotherapy of advanced non small cell lung cancer: effect on survival and symptoms affecting quality of life]. / Ocena wplywu chemioterapii na czas przezycia i wybrane objawywplywajace na jakosc zycia chorych na niedrobnokomórkowegoraka pluca w IIIB i IV stopniu zaawansowania.

INTRODUCTION: The study presents treatment results of 168 patients with non small cell lung cancer in stage IIIB and IV treated since year 2002 to 2006 in Oncological Center in Cracow. MATERIAL AND METHODS: Four regimens of chemotherapy: EP (cisplatin, vepesid), MVP (mitomycin C, vinblastin, cisplatin), PN (cisplatin,vinorelbin) and PG (cisplatin, gemcytabin) were used. RESULTS: Average survival time in group treated with MVP regimen was 7,8 months (median 4,3 months), PG 7,1 months (median 7,3 months), EP 10,2 months (median 7,5 months), PN 14,1 months (median 9,8 months). Differences in median survival time were not significant. Average time to progression in group treated with MVP regimen was 3,5 months (median 2,6 months), PG 5,2 months (median 5,8 months): EP 6,6 months (median 5,2 months), PN 6,7 months (median 5,6 months). Improvement in control of symptoms regarding dyspnea, pain and cough was reached in 60%, 38,7% and 60% of patients respectively. There were no significant differences between chemotherapy regimens regarding improvement in symptoms control. CONCLUSIONS: Cisplatin + vinorelbin regimen can be recommended as standard method because of the best treatment results.